Industry veteran Patrik Forsell oversees Takeda’s operations in Denmark. Here, Forsell talks through how sizeable shifts in the company’s global portfolio and focus over the past four years have played out at the Danish level, the increasingly challenging market access situation for rare disease treatments in the country, and how he managed the affiliate through the COVID-19 pandemic.
I see [market access] delays as a threat to Denmark’s ability to continue to attract international investment and clinical trials
